Abstract
Hypertrophic cardiomyopathy (HCM) is the most prevalent inherited cardiomyopathy transmitted in an autosomal dominant manner to offspring. It is characterized by unexplained asymmetrical hypertrophy primarily affecting the left ventricle and interventricular septum while potentially causing obstruction within the left ventricular outflow tract (LVOT). The clinical manifestations of HCM are diverse, ranging from asymptomatic to severe heart failure (HF) and sudden cardiac death. Most patients present with obvious symptoms of left ventricular outflow tract obstruction (LVOTO). The diagnosis of HCM mainly depends on echocardiography and other imaging examinations. In recent years, myosin inhibitors have undergone clinical trials and gene therapy, which is expected to become a new treatment for HCM, has been studied. This article summarizes recent clinical updates on the epidemiology, pathogenesis, diagnostic methods, treatment principles, and complication prevention and treatment of HCM, to provide new ideas for follow-up research.